The Motley Fool
04 Jul 2026, 20:11 UTC · 2h ago
Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
04 Jul 2026, 20:11 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The Invesco Pharmaceuticals ETF (PJP) has shown stronger recent price appreciation compared to the VanEck Pharmaceutical ETF (PPH) due to its focus on U.S. stocks and the GLP-1 weight loss drug trend. — Positive momentum in specific pharmaceutical sub-sectors like GLP-1s drives short-term price action for concentrated U.S. funds.
+0.30The VanEck Pharmaceutical ETF (PPH) offers a lower expense ratio (0.36%) and a higher dividend yield (2.00%) than the Invesco Pharmaceuticals ETF. — Lower costs and higher yields are marginally positive for long-term total return and risk-adjusted appeal.
+0.10The VanEck Pharmaceutical ETF (PPH) provides global exposure with 38% of holdings in international markets, whereas the Invesco Pharmaceuticals ETF (PJP) is 100% U.S.-based. — Diversification across geographies changes the risk profile regarding currency and foreign tax exposure but is a structural choice rather than a market shock.
+0.05Continue reading
6 related stories
Top 3 movers · tap to explore
Which stocks this story touches
Mentioned as a top holding in both ETFs and linked to the positive 'GLP-1 weight loss revolution'.
Mentioned as a top holding in the PJP fund, which the article notes has demonstrated stronger recent price appreciation.
Mentioned as a top holding in a fund demonstrating positive momentum and returns.
Mentioned as a top holding in a fund demonstrating positive momentum and returns.
Mentioned as a top holding in the PJP fund, which the article notes has demonstrated stronger recent price appreciation.
[mutual] Both companies are major holdings in pharmaceutical ETFs targeting the same drug development and research market.
[mutual] Both companies are major holdings in pharmaceutical ETFs targeting the same drug development and research market.
[mutual] Both companies are major holdings in pharmaceutical ETFs targeting the same drug development and research market.
[mutual] Both companies are major holdings in pharmaceutical ETFs targeting the same drug development and research market.
[mutual] Both companies are major holdings in pharmaceutical ETFs targeting the same drug development and research market.
[mutual] Both companies are major holdings in pharmaceutical ETFs targeting the same drug development and research market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
24/7 Wall Street
4h ago
